Melatonin and bone status;Melatonina a stan kośćca

Polski Merkuriusz Lekarski

Volumn 21, Issue 124, 2006, Pages 389-393

  Ostrowska, Zofia ^a   Wołkowska Pokrywa, Kinga ^a   Kos Kudła, Beata ^a   Świȩtochowska, Elzbieta ^a   Marek, Bogdan ^a   Kajdaniuk, Dariusz ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Bone tissue; Melatonin; RANKL RANK OPG system

Indexed keywords

MELATONIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

BONE REMODELING; DOWN REGULATION; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; REVIEW;

ANIMALS; BONE AND BONES; BONE DENSITY; BONE RESORPTION; FEMALE; HUMANS; MELATONIN; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; OSTEOPOROSIS; PINEAL GLAND; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B;

EID: 33751055010     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Badurski J., Sawicki A., Boczoń S.: Osteoporaza. Osteoprint, Białystok 1994.
2. Bagnall., Raso V.J., Moreau M. i wsp.: The effect of melatonin therapy on the development of scoliosis after pinealectomy in the chicken. J. Bone Joint Surg. Am., 1999, 81, 191-199.
3. Birau N., Pettersen U., Meyer C. i wsp.: Hypotensive effect of melatonin in essential hypertension. IRCS Med. Sci., 1981, 9, 906.
4. Brusco L.I., Marquez M., Cardinali D.P.: Melatonin treatment stabilizes chronobiologic and cognitive symptoms in Alzheimer's disease. Neuroendocrinol. Lett., 1998, 19, 111-115.
5. Brydon L., Petit L., de Coppet P. i wsp.: Polymorphism and signaling of melatonin receptors Reprod. Nutr. Dev., 1999, 39, 315-324.
6. Cagnacci A., Arangino S., Angiolucci M. i wsp.: Influences of melatonin administration on the circulation of women. Am. J. Physiol., 1998, 43, 335-338.
7. Cardinali D.P., Ladizesky M.G., Boggio V. i wsp.: Melatonin effects on bone: experimental facts and clinical perspectives. J. Pineal Res., 2003, 34, 81-87.
8. Carlberg C., Wiesenberg I., Schräder M., Nuclear signaling of melatonin. Front. Horm. Res., 1997, 23, 25-35.
9. Cohen M., van Heusden A.M., Verdok H.E.R. i wsp.: Melatonin/noretisterone contraception. In: Touitou Y., Arendt J., Pevet P. (red.): Melatonin and the pineal gland - from basic science to clinical application. Elsevier, Amsterdam 1993, 339-345.
10. Conti A., Conconi S., Hertens E. i wsp.: Evidence for melatonin synthesis in mouse and human bone marrow cells. J. Pineal Res., 2000, 28, 193-202.
11. Dubocovich M.L., Masana M.I., Bencloucif S.: Molecular pharmacology and function of melatonin receptor subtypes. Adv. Exp. Med. Biol., 1999 460, 181-190.
12. Pagan A.B., Kennaway D.J., Sutherland A.D.: Total 24-hour melatonin secretion in adolescent idiopatic scoliosis. A case-control study. Spine 1998, 23, 41-46.
13. Galus K., Choroby metaboliczne kości. Med. Tur. Pres. International, Warszawa 1995.
14. Hardeland R., Pandi-Perumal S.R., Cardinali D.P.: Melatonin. Int. J. Biochem. Cell Biol., 2006, 38, 313-316.
15. Hilibrand A.S., Blakemore L.C., Loder R.T. i wsp.: The role of melatonin in the pathogenesis of adolescent idiopatic scoliosis. Spine, 1996, 21 1140-1146.
16. Hofbauer L.C.: Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism. Eur. J. Endocrinol., 1999, 141(3), 195-210.
17. Hofbauer L.C., Heufeldder A.E.: Role of receptor activator of nuclear factor-kB ligand and osteoprotegerin in bone cell biology. J. Mol. Med., 2001, 79, 243-253.
18. Kanemura T., Kawakami N., Deguchi M. i wsp.: Natural course of experimental scoliosis in pinealectomized chickens. Spine, 1997, 22, 1563-1567.
19. Karasek M.: Szyszynka a wzrost nowotworowy. Endokrynol. Pol., 1995, 46, suppl. 1, 137-145.
20. Karasek M.: Szyszynka i melatonina. PWN, Warszawa - Łó dź 1997.
21. Karasek M., Kuzdak K., Cywiński J. i wsp.: Effect of melatonin administration in advanced breast cancer patients - preliminary report. Neuroendocrinol. Lett., 1998, 19, 15-19.
22. Karasek M., Lewiński A., Reiter J.R.: Melatonina: znaczenie kliniczne i zastosowanie terapeutyczne. Endokrynol. Pol., 2001, 52, 81-100.
23. Karasek M., Reiter R.J.: Melatonin and aging. Neuroendocrinol. Lett., 2002, 23, suppl. 1, 14-16.
24. Koyama H., Nakade O., Takada Y. i wsp.: Melatonin at pharmacologic doses increases bone mass by suppressing resorption through down-regulation of the RANKL-mediated osteoclast formation and activation. J. Bone Mineral. Res., 2002, 17, 1219-1229.
25. Ladizesky M.G., Cutrera R.A., Boggio V. i wsp.: Effect of melatonin on bone metabolism in ovariectomized rats. Life Sci., 2001, 70, 557-565.
26. Ladizesky M.G., Boggio V., Albornoz L.E. i wsp.: Melatonin increases oestradiol-induced bone formation in ovariectomized rats. J. Pineal Res., 2003, 34, 143-151.
27. Lerner A.B., Case J.D., Takahashi Y. i wsp.: Isolation of melatonin, pineal factor that lightens melanocytes. J. Am. Chem. Soc., 1958, 80, 2587.
28. Lerner A.B., Case J.D., Heinzelman R.U.: Structure of melatonin. J. Am. Chem. Soc., 1959, 81, 6084-6085.
29. Lissoni P., Paolorossi P., Meregalli S. i wsp.: Melatonin as a modulator of cancer endocrine therapy. Front. Horm. Res., 1997, 23, 132-136.
30. Machida M., Dubousser J., Immamura Y. i wsp.: Role of melatonin deficiency in the development of scoliosis of pinealectomized chickens. J. Bone Surg. Br., 1995, 77, 134-138.
31. Maestroni G.: Melatonin and immune function. In: Ader R., Felten D.L., Cohen N., (red.): Psychoneuroimmunology, Academic Press, San Diego, 2001, 433-443.
32. Manolagas S.C.: Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr. Rev., 2000, 21, 115-137.
33. Nakade O., Kayoma H., Ariji H. i wsp.: Melatonin stimulates proliferation and type I collagen synthesis in human cells in vitro. J. Pineal Res., 1999, 27, 106-110.
34. O'Kelly C., Wang X., Raso V.J. i wsp.: The production of scoliosis after pinealectomy in young chicken, rats, and hamsters. Spine, 1999, 24, 35-43.
35. Ostrowska Z., Buntner B., Banaś I. i wsp.: Circadian variations of salivary melatonin levels in women of reproductive and postmenopausal age with gynoid and android obesity. Endocr. Regul., 1996, 30, (3), 143-152.
36. Ostrowska Z., Świçtochowska E., Buntner B. i wsp.: Assessment of relationship between secretion of melatonin, activity of thyroid, adrenal cortex as well as testes and chosen markers of collagen metabolism in starved rats. Endocr. Regul., 1996, 30, 83-92.
37. Ostrowska Z., Kos-Kudła B., Świȩtochowska E. i wsp.: Assessment of the relationship between dynamic pattern of nighttime levels of melatonin and chosen biochemical markers of bone metabolism in a rat model of postmenopausal osteoporosis. Neuroendocrinol. Lett., 2001, 22, 131-138.
38. Ostrowska Z., Kos-Kudła B., Marek B. i wsp.: Assessment of the relationship between circadian variations of salivary melatonin levels and type I collagen metabolism in postmenopausal obese women. Neuroendocrinol. Lett., 2001, 22, 121-127.
39. Ostrowska Z., Kos-Kudła B., Marek B. i wsp.: The influence of pinealectomy and melatonin administration on the dynamic pattern of biochemical markers of bone metabolism in experimental osteoporosis in the rat. Neuroendocrinol. Lett., 2002, 23, suppl. 1, 104-109.
40. Ostrowska Z., Kos-Kudła B., Marek B. i wsp.: The relationship between daily profile of chosen biochemical markers of bone metabolism and melatonin and other hormone secretion in rats under physiological conditions. Neuroendocrinol. Lett., 2002, 23, 417-425.
41. Ostrowska Z., Kos-Kudła B., Marek B. i wsp.: Influence of lighting conditions on daily rhytmicity of bone metabolism in rats and possible involvement of melatonin and other hormones in this process. Endocr. Regul., 2003, 37, 163-174.
42. Ostrowska Z., Kos-Kudła B., Nowak M. i wsp.: The relationship between bone metabolism, melatonin and other hormones in sham-operated and pinealectomized rats. Endocr. Regul., 2003, 37, 211-224.
43. Ostrowska Z., Kos-Kudła B., Marek B. i wsp.: Perspektywy stosowania melatoniny w profilaktyce i leczeniu osteoporozy. Przegl. Menop., 2003, 5, 43-46.
44. Ostrowska Z., Kos-Kudła B., Marek B. i wsp.: Gȩstoś ć mineralna kości a dobowe stȩżenia melatoniny, osteoprotegeryny i RANKL u otyłych kobiet po menopauzie. 35 Zjazd Towarzystwa Internistów Polskich, 9-12 września 2004 r, Katowice. Pol. Arch. Med. Wewn., 2004 112, suppl.1, 413.
45. Ostrowska Z., Kos-Kudła B., Świȩtochowska E. i wsp.: Influence of pinealectomy and long-term melatonin administration on bone metabolism in orchidectomized rats. Endokrynol. Pol., 2006, 57 (1), 7-14.
46. Reiter R.J.: Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr. Rev., 1991, 12, 151-180.
47. Reiter R.J., The melatonin rhythm: both a clock and a calendar. Experientia (Basel), 1993, 49, 654-664.
48. Reiter R.J., Robinson J.: Melatonina twój naturalny cudowny lek. AMBER, Warszawa 1997.
49. Roth J.A., Kim B.C., Lin W.L. i wsp.: Melatonin promotes osteoblast differentiation and bone formation. J. Biol. Chem., 1999, 274, 22041-22047.
50. Roux S., Orcel P.: Bone loss: Factors that regulate osteoclast differentiation - an update. Arthritis Res. 2000, 2, 451-456.
51. Sadat-Ali M., al-Habdan I., al-Othman A.: Adolescent idiopatic scoliosis. Is low melatonin a cause? Joint Bone Spine, 2000, 67, 62-64.
52. Sandyk R., Anastasiadis P.G., Annimos P.A. i wsp.: Is postmenopausal osteoporosis related to pineal gland functions? Int. J. Neurosc., 1992, 62, 215-225.
53. Schmidt H.A., Requintina P.J., Oxenkurg G.F. i wsp.: Calcium, calcification, and melatonin biosynthesis in the human pineal gland: a postmortem study into age-related factors. J. Pineal Res., 1994, 16, 178-183.
54. Suzuki N., Hattori A.: Melatonin suppresses osteoclastic and osteoblastic activities in the goldfish scale. J. Pineal Res., 2002, 33, 253-258.
55. Tan D.X., Manchester L.C., Reiter R.J. i wsp.: Identification of highly elevated levels of melatonin in bone marrow: Its origin and significance. Biochim. Biophys., 1999, 1472, 206-214.
56. Tsukii K., Shima N., Mochizuki S. i wsp.: Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1, 25-dihydroxyvitamin D3, prostaglandin E2 or parathyroid hormone in the microenvironment of bone. Biochem. Biophys. Res. Commun., 1998, 246, 337-341.
57. Wang X., Jiang H., Raso J. i wsp.: Characterization of the scoliosis that develops after pinealectomy in the chicken and comparison with adolescent idiopatic scoliosis in humans. Spine, 1997, 22, 2626-2635.
58. Wang X., Moreau M., Raso V.J. i wsp.: Changes in serum melatonin levels in response to pinealectomy in the chicken and its correlation with development of scoliosis. Spine, 1998, 23, 2377-2381.
59. Yasuda H., Shima N., Nakagawa N. i wsp.: Identification of osteoclastogenesis-inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology, 1998, 139, 1329-1337.